Background:Hyperlipidemia(HLP)is a disorder in which lipids in the blood are disturbed due to abnormal lipid metabolism.Statins and fibrates lipid-regulating drugs prevent the generation of lipids and improves HLP,the...Background:Hyperlipidemia(HLP)is a disorder in which lipids in the blood are disturbed due to abnormal lipid metabolism.Statins and fibrates lipid-regulating drugs prevent the generation of lipids and improves HLP,thereby reducing the likelihood of developing cardiovascular and cerebrovascular diseases.However,their adverse reactions and side effects limit a wide range of clinical applications.Tibetan medicine compound preparation Siwei Yuganzi decoction(SYD)is an adaptation of a classical prescription of the Tibetan medicine Sanguo decoction,that has been proved to have the effect of improving lipid metabolism;however,its possible mechanism remains unknown.Methods:Sixty specific-pathogen free grade Sprague Dawley rats were randomly divided into the blank control group,the HLP group,the Chinese patent medicine Xuezhikang positive control group,and the treatment groups with Tibetan SYD high-,middle-,and low-dosages respectively.Ten rats were assigned to each group.Every rat in these groups was fed with a high-fat emulsion to establish the hyperlipidemic animal model,except for those in the blank control group.Then the rats in the blank control and HLP groups were fed with 0.9%normal saline,those in Xuezhikang group were fed with Xuezhikang suspension at the dose of 0.11 g/kg/d,and those in SYD groups were fed with the SYD suspension at the dosage of 16.2 g/kg/d(high dosage),10.8 g/kg/d(middle dosage),and 5.4 g/kg/d(low dosage),respectively.After 8 weeks,the levels of serum total cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C),and high-density lipoprotein cholesterol(HDL-C)were detected by the ELISA.The mRNA and protein expression levels of liver X receptorα(LXRα)and cholesterol 7α-hydroxylase 1(CYP7A1)were detected using RT-PCR,western blotting,and immunohistochemistry.Results:The serum levels of TC,TG,and LDL-C in the HLP group were higher than those in the blank control group(P<0.05),whereas the serum levels of HDL-C and the expression levels of both LXRαand CYP7A1 mRNA and proteins in the liver in the HLP group were lower than those in the control group(P<0.05).After the treatment of the Xuezhikang and SYD,the serum levels of TG,TC,and LDL-C significantly decreased(P<0.05),whereas the serum levels of HDL-C and the expression levels of both LXRαand CYP7A1 mRNA and proteins in the liver significantly increased compared with those in the HLP group(P<0.05).Furthermore,The serum levels of TC,TG,and LDL-C in the SYD group at high dosage were lower(P<0.05),the serum level of HDL-C was higher,and the expression levels of both LXRαand CYP7A1 mRNA and proteins in the liver tissue were higher than those in the Xuezhikang group(P<0.05).Conclusion:SYD can improve the serum levels of TC,TG,and LDL-C in the hyperlipidemic animal model via increasing the expression of both LXRαand CYP7A1 mRNA and proteins in the liver tissue.展开更多
目的探讨协日嘎四味汤散联合加味柴芍六君汤对原发性肝癌微创消融术后患者的疗效及安全性。方法本研究纳入原发性肝癌患者共70例,按相同男女比例随机分为对照组和观察组,每组各35例。微创消融术后1周,对照组给予常规治疗,观察组给予协...目的探讨协日嘎四味汤散联合加味柴芍六君汤对原发性肝癌微创消融术后患者的疗效及安全性。方法本研究纳入原发性肝癌患者共70例,按相同男女比例随机分为对照组和观察组,每组各35例。微创消融术后1周,对照组给予常规治疗,观察组给予协日嘎四味汤散联合加味柴芍六君汤进行治疗,疗程为一个月。通过检测谷丙转氨酶(Alanine transaminase,ALT)、谷草转氨酶(Aspartate Transaminase,AST)、碱性磷酸酶(Alkaline phosphatase,ALP)、直接胆红素(Direct Bilirubin,DBIL)和血清甲胎蛋白(Alpha-fetoprotein,AFP)等分子对肝功能以及肝癌发展进行评估;采用肝癌生命质量测定量表(Quality of Life in Liver Cancer Measurement Scale,QOL-LC)评估患者生存质量;采用中医症状积分量表评估症状严重程度。结果治疗后,观察组在血清功能相关指标方面表现出显著改善,具体表现为ALT、AST、ALP、DBIL和AFP含量显著低于对照组(P<0.05)。在生命质量评分方面,观察组在躯体功能、症状/副作用和社会功能评分上均显著优于对照组(P<0.05)。在中医症状分级方面,观察组中医症状分级为轻度和中度的患者占比明显多于对照组(P<0.05)。在安全性评估中,观察组出现不良反应的患者数亦显著少于对照组(P<0.05)。结论本研究表明了协日嘎四味汤散联合加味柴芍六君汤在原发性肝癌微创消融术后的治疗中具有一定疗效。展开更多
文摘Background:Hyperlipidemia(HLP)is a disorder in which lipids in the blood are disturbed due to abnormal lipid metabolism.Statins and fibrates lipid-regulating drugs prevent the generation of lipids and improves HLP,thereby reducing the likelihood of developing cardiovascular and cerebrovascular diseases.However,their adverse reactions and side effects limit a wide range of clinical applications.Tibetan medicine compound preparation Siwei Yuganzi decoction(SYD)is an adaptation of a classical prescription of the Tibetan medicine Sanguo decoction,that has been proved to have the effect of improving lipid metabolism;however,its possible mechanism remains unknown.Methods:Sixty specific-pathogen free grade Sprague Dawley rats were randomly divided into the blank control group,the HLP group,the Chinese patent medicine Xuezhikang positive control group,and the treatment groups with Tibetan SYD high-,middle-,and low-dosages respectively.Ten rats were assigned to each group.Every rat in these groups was fed with a high-fat emulsion to establish the hyperlipidemic animal model,except for those in the blank control group.Then the rats in the blank control and HLP groups were fed with 0.9%normal saline,those in Xuezhikang group were fed with Xuezhikang suspension at the dose of 0.11 g/kg/d,and those in SYD groups were fed with the SYD suspension at the dosage of 16.2 g/kg/d(high dosage),10.8 g/kg/d(middle dosage),and 5.4 g/kg/d(low dosage),respectively.After 8 weeks,the levels of serum total cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C),and high-density lipoprotein cholesterol(HDL-C)were detected by the ELISA.The mRNA and protein expression levels of liver X receptorα(LXRα)and cholesterol 7α-hydroxylase 1(CYP7A1)were detected using RT-PCR,western blotting,and immunohistochemistry.Results:The serum levels of TC,TG,and LDL-C in the HLP group were higher than those in the blank control group(P<0.05),whereas the serum levels of HDL-C and the expression levels of both LXRαand CYP7A1 mRNA and proteins in the liver in the HLP group were lower than those in the control group(P<0.05).After the treatment of the Xuezhikang and SYD,the serum levels of TG,TC,and LDL-C significantly decreased(P<0.05),whereas the serum levels of HDL-C and the expression levels of both LXRαand CYP7A1 mRNA and proteins in the liver significantly increased compared with those in the HLP group(P<0.05).Furthermore,The serum levels of TC,TG,and LDL-C in the SYD group at high dosage were lower(P<0.05),the serum level of HDL-C was higher,and the expression levels of both LXRαand CYP7A1 mRNA and proteins in the liver tissue were higher than those in the Xuezhikang group(P<0.05).Conclusion:SYD can improve the serum levels of TC,TG,and LDL-C in the hyperlipidemic animal model via increasing the expression of both LXRαand CYP7A1 mRNA and proteins in the liver tissue.
文摘目的探讨协日嘎四味汤散联合加味柴芍六君汤对原发性肝癌微创消融术后患者的疗效及安全性。方法本研究纳入原发性肝癌患者共70例,按相同男女比例随机分为对照组和观察组,每组各35例。微创消融术后1周,对照组给予常规治疗,观察组给予协日嘎四味汤散联合加味柴芍六君汤进行治疗,疗程为一个月。通过检测谷丙转氨酶(Alanine transaminase,ALT)、谷草转氨酶(Aspartate Transaminase,AST)、碱性磷酸酶(Alkaline phosphatase,ALP)、直接胆红素(Direct Bilirubin,DBIL)和血清甲胎蛋白(Alpha-fetoprotein,AFP)等分子对肝功能以及肝癌发展进行评估;采用肝癌生命质量测定量表(Quality of Life in Liver Cancer Measurement Scale,QOL-LC)评估患者生存质量;采用中医症状积分量表评估症状严重程度。结果治疗后,观察组在血清功能相关指标方面表现出显著改善,具体表现为ALT、AST、ALP、DBIL和AFP含量显著低于对照组(P<0.05)。在生命质量评分方面,观察组在躯体功能、症状/副作用和社会功能评分上均显著优于对照组(P<0.05)。在中医症状分级方面,观察组中医症状分级为轻度和中度的患者占比明显多于对照组(P<0.05)。在安全性评估中,观察组出现不良反应的患者数亦显著少于对照组(P<0.05)。结论本研究表明了协日嘎四味汤散联合加味柴芍六君汤在原发性肝癌微创消融术后的治疗中具有一定疗效。
